“…Serum or plasma was screened for antibodies against the paramyxoviruses (CedV, HeV, NiV, MenV and TioV), the betacoronaviruses (SARS‐CoV‐1 and MERS‐CoV), and a lyssavirus, ABLV, at the CSIRO ACDP using multiplex microsphere‐based immunoassays (MMIA) (Luminex Corporation, Austin, TX, USA) as described previously (Boardman et al., 2020a , 2020b ; Bossart et al., 2007 ; Boyd et al., 2015 ; Burroughs et al., 2016 ; Dovih et al., 2019 ; Edson et al., 2019 ; Laing et al., 2018 ; Peel et al., 2012 , 2013 ; Prada et al., 2019a , 2019b ; Schulz et al., 2020 ). Briefly, a recombinant, soluble, tetrameric MenV haemagglutinin‐neuraminidase (sHN) attachment glycoprotein was constructed and prepared as previously devised for other henipavirus G glycoproteins (Cheliout Da Silva et al., 2021 ) (Supplementary Text S1 ); soluble, tetrameric, receptor‐binding protein (RBP) glycoproteins of HeV, NiV, and CedV (sG) (Laing et al., 2019 ; Schulz et al., 2020 ; Yan et al., 2021 ), nucleocapsid protein (N) of TioV (Petraityte et al., 2009 ) and lyssaviruses (Prada et al., 2019 ; Rahmadane et al., 2017 ), and SARS‐CoV‐1 N and MERS‐CoV N (Yu et al., 2008 ) were produced as previously described.…”